(NASDAQ: ALEC) Alector's forecast annual revenue growth rate of 11.64% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 35.36%, and while it is forecast to beat the US market's average forecast revenue growth rate of 9.64%.
Alector's revenue in 2024 is $96,406,000.On average, 4 Wall Street analysts forecast ALEC's revenue for 2024 to be $6,321,863,422, with the lowest ALEC revenue forecast at $6,127,166,606, and the highest ALEC revenue forecast at $6,448,127,198. On average, 4 Wall Street analysts forecast ALEC's revenue for 2025 to be $9,190,460,756, with the lowest ALEC revenue forecast at $4,129,114,636, and the highest ALEC revenue forecast at $19,276,912,400.
In 2026, ALEC is forecast to generate $13,160,733,634 in revenue, with the lowest revenue forecast at $10,343,027,348 and the highest revenue forecast at $18,478,848,227.